Amerikanische Gesellschaft für Hirudotherapie

Identification and characterization of WpDestabilase, a novel destabilase from the salivary glands of Whitmania pigra

Recombinant expression study published in Protein Expression and Purification (2026)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportGenomik & ProteomikSpeichel-PharmakologieArzneimittelentwicklungHuang B et al. · Protein expression and purification, 2026

Abstract

Whitmania pigra is one of the primary sources of leeches used in traditional Chinese medicine, renowned for its anticoagulant and thrombolytic properties. In this study, a salivary gland transcriptome database of W. pigra was constructed, and 7 anticoagulation-related transcripts were identified, one of which was designated as "WpDestabilase". The unigenes producing these transcripts were functionally annotated to proteins with potential pharmacological activities, including fibrinolytic enzymes, neutrophil elastase inhibitors, elastase inhibitors, and factor Xa inhibitors. The cDNA sequence of the WpDestabilase gene (TRINITY_DN17453_c0_g1) showed significant homology to Destabilase I from Hirudo medicinalis, and its TPM value was significantly higher than that of the other identified transcripts. The WpDestabilase cDNA is 450 bp in length, encoding a protein of 149 amino acids. The amino acid sequence of the mature WpDestabilase protein contains seven disulfide bonds and a motif CTGGRTPTCQDYARIHxGGP, which are characteristic structural features of destabilases. The recombinant WpDestabilase protein exhibited isopeptidase activity together with blood-clot-destabilizing efficacy, suggesting that WpDestabilase may represent a major candidate molecule contributing to the thrombolytic activity of W. pigra. Removal of a 10-amino acid sequence (IPATETTTEI) at the C-terminal tail of the WpDestabilase protein significantly enhanced its isopeptidase activity while its lysozyme activity was not significantly reduced. This may reflect the evolutionary transition of anticoagulant genes to non-anticoagulant genes during the non-hematophagous adaptive evolution of W. pigra. These findings pave the way for further development and utilization of leeches and destabilases.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article

Zusammenfassung

Recombinant expression and biochemical characterization of WpDestabilase from Whitmania pigra. Demonstrates fibrinolytic and antibacterial activities via isopeptidolysis, mirroring H. medicinalis destabilase.

Warum dies für die Hirudotherapie relevant ist

This study constructed a salivary gland transcriptome database for the leech Whitmania pigra and identified a transcript designated WpDestabilase, which showed significant homology to Destabilase I from Hirudo medicinalis. The recombinant WpDestabilase protein exhibited isopeptidase activity and blood-clot-destabilizing efficacy, and the abstract states it may represent a major candidate molecule contributing to the thrombolytic activity of W. pigra. Removal of a C-terminal ten-amino-acid sequence enhanced its isopeptidase activity. The abstract notes these findings pave the way for further development and utilization of leeches and destabilases. The limitation is that the work described is confined to recombinant protein characterization and activity assays, with no clinical or in-vivo data presented in the abstract.

Zitation

Identification and characterization of WpDestabilase, a novel destabilase from the salivary glands of Whitmania pigra.

Huang B et al. · Protein expression and purification, 2026

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.